Amylyx Pharmaceuticals (AMLX) Enterprise Value (2021 - 2025)
Amylyx Pharmaceuticals (AMLX) has 5 years of Enterprise Value data on record, last reported at -$317.0 million in Q4 2025.
- For Q4 2025, Enterprise Value fell 79.59% year-over-year to -$317.0 million; the TTM value through Dec 2025 reached -$317.0 million, down 79.59%, while the annual FY2025 figure was -$317.0 million, 79.59% down from the prior year.
- Enterprise Value reached -$317.0 million in Q4 2025 per AMLX's latest filing, up from -$344.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$96.1 million in Q4 2021 and bottomed at -$373.3 million in Q1 2024.
- Average Enterprise Value over 5 years is -$272.8 million, with a median of -$309.8 million recorded in 2024.
- Peak YoY movement for Enterprise Value: plummeted 260.96% in 2022, then surged 52.47% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$96.1 million in 2021, then tumbled by 260.96% to -$346.9 million in 2022, then fell by 7.04% to -$371.4 million in 2023, then soared by 52.47% to -$176.5 million in 2024, then plummeted by 79.59% to -$317.0 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$317.0 million in Q4 2025, -$344.0 million in Q3 2025, and -$180.8 million in Q2 2025.